While complying with local directives, Cellecta is fully operational. Normal turnaround times have not been affected by COVID-19 more >
Stop by and see us at Booth 4218.
Presentations:
Efficient tools to enable drug target and biomarker discovery: a brief introduction to Cellecta technologies
Paul Diehl, Ph.D., COO, Cellecta, Inc.
Quantitative and multiplexed in vivo functional cancer genomics using barcoded CRISPR libraries
Ian P. Winters, Ph.D., Director of Research, D2G Oncology
Large-scale sequencing of human tumors has uncovered a vast array of genomic alterations. Genetically engineered mouse models recapitulate many features of human cancer and have been instrumental in assigning biological meaning to specific cancer-associated alterations. However, their time, cost- and labor-intensive nature limits their broad utility; thus, the functional importance of the majority of genomic aberrations in cancer remains unknown. Here, we combine genetically engineered mouse models of cancer with CRISPR-mediated genome editing, DNA barcoding, and next-generation sequencing to simultaneously investigate the function of many genomic alterations in vivo and uncover novel biological and clinically actionable insights into carcinogenesis.
Thank you for your interest in Cellecta technologies. We look forward to seeing you at the 2019 AACR Annual Meeting
Where: Spotlight Theatre C, AACR Exhibit Hall
When: Tuesday, April 2, 2019, 3:00 to 4:00 pm
Feel free to forward this invitation to your interested colleagues.
For more information on Cellecta, stop by and see us at AACR Booth 4218.
Please enter your contact information below.
* required
Thank you for your interest in Cellecta's educational event at 2019 AACR Annual Meeting. Registration is closed. Please contact us at marketing@cellecta.com if you would like to receive educational materials.
